Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Chronic Lymphoid Leukemia Clinical Trial

— CLL-Frail  

Official title:

CLL-Frail - A Prospective, Multicenter Phase II Trial of Acalabrutinib in Very Old (≥80y) or Frail CLL-Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04883749
• Other study ID #: CLL-Frail
• Secondary ID: 2020-002142-17
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 1, 2021
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: German CLL Study Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score >2 (5-item questionnaire to be filled out by the patient)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: December 2024
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =80 years AND/OR considered too frail for intensive/standard treatment defined by a frailty score of >2 on the FRAIL scale via the patient´s assessment.

2. Have documented CLL requiring treatment according to iwCLL 2018 criteria

3. Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements

4. Glomerular Filtration Rate (GFR) >30ml/min directly measured with 24hr urine collection, calculated according to the modified formula of Cockcroft and Gault (for men: GFR ˜ ((140 - age) x bodyweight)/ (72 x creatinine), for women x 0, 85) or an equally accurate method (Please note: Patients currently on hemodialysis are excluded from participating in the trial)

5. Adequate liver function as indicated by a total bilirubin = 3 x, Aspartate-Aminotransferase/Alanin-Aminotransferase (AST/ ALT) = 3 x the institutional Upper Limit of Normal (ULN) value, unless directly attributable to the patient's CLL or to Gilbert's Syndrome

6. Adequate marrow function independent of growth factor or transfusion support as

follows, unless cytopenia is due to marrow involvement of CLL:

• Absolute neutrophil count = 1.0 × 10^9/L
• Platelet counts = 30 × 10^9/L; in cases of thrombocytopenia clearly due to marrow involvement of CLL (per the discretion of the investigator); platelet count should be = 10 × 10^9/L if there is bone marrow involvement
• Total haemoglobin = 9 g/dL (without transfusion support, unless anaemia is due to marrow involvement of CLL)

7. Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA Polymerase Chain Reaction (PCR) is performed every month until 12 months after last month of treatment), negative testing for hepatitis C RNA within 6 weeks prior to registration

8. Life expectancy = 3 months

9. Maximum of 1 previous treatment for CLL

10. In case of a recent previous treatment, patients must have recovered from acute toxicities and treatment regimen must be stopped within the following time periods

before start of the study treatment in the CLL-Frail trial:

• chemotherapy = 28 days
• antibody treatment = 14 days
• kinase inhibitors (see also exclusion criterion 6), BCL2-antagonists or immunomodulatory agents = 3 days
• corticosteroids may be applied until the start of the study therapy, these have to be reduced to an equivalent of = 20 mg prednisolone per day during treatment

11. Signed informed consent and, in the investigator's judgment, able to comply with the study protocol

Exclusion Criteria:

1. >1 prior CLL-specific therapy (except corticosteroid treatment administered due to necessary immediate intervention; within the last 14 days before start of study treatment, only dose equivalents up to 20 mg prednisolone are permitted)

2. Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) e.g. Richter's transformation or prolymphocytic leukaemia

3. Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML)

4. Patients with uncontrolled autoimmune haemolytic anaemia or immune thrombocytopenia

5. Prior exposure to acalabrutinib

6. Progression during previous treatment with another BTK inhibitor, and/or presence of known mutations associated with resistance to therapy, e.g. Bruton´s Tyrosine Kinase (BTK) and Phospholipase C Gamma 2 (PLCg2)

7. Uncontrolled concomitant malignancy, i.e. any concomitant malignancy that may compromise the assessment of CLL stage and the response assessment of the study treatment

8. Eastern Cooperative Oncology Group Performance Status (ECOG) performance status >3

9. Uncontrolled or active infection (including positive SARS-Cov-2 PCR result)

10. Patients with known infection with human immunodeficiency virus (HIV)

11. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 3 months of screening, or any class 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening (Please note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study)

12. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening

13. Significantly increased risk of bleeding according to the investigator´s evaluation, e.g. due known bleeding diathesis (e.g. von-Willebrandt´s disease or hemophilia), major surgical procedure = 4 weeks or stroke/intracranial hemorrhage = 6 months

14. Use of investigational agents which might interfere with the study drug within 28 days prior to registration for study screening

15. Requirement of therapy with strong CYP3A4 inhibitors/inducers or anticoagulant with phenprocoumon (marcumar) or other vitamin K-antagonists (Please note: Switch to alternative anticoagulants for vitamin K antagonists is permitted)

16. Inability to swallow tablets

17. Legal incapacity

18. Prisoners or subjects who are institutionalized by regulatory or court order

19. Persons who are in dependence to the sponsor or an investigator

Related Conditions & MeSH terms

• Chronic Lymphoid Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Biological:
• Acalabrutinib
Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)

Locations

Country	Name	City	State
Austria	Medizinische Universität Innsbruck	Innsbruck
Austria	Hanusch Krankenhaus	Wien
Germany	Onkologische Schwerpunktpraxis Kurfürstendamm	Berlin
Germany	Donau-Isar-Klinikum Deggendorf Hämatologie/Onkologie	Deggendorf
Germany	Oncoresearch Institut für klinische Studien GbR	Erlangen
Germany	Universitaetsklinikum Essen	Essen
Germany	Onkologische Kooperation Harz	Goslar
Germany	OncoResearch Lerchenfeld	Hamburg
Germany	MediProjekt GBR	Hannover
Germany	Universitaetsklinikum Schleswig-Holstein Campus Kiel	Kiel
Germany	Praxis fuer Haematologie und Onkologie	Koblenz
Germany	Universitätsklinik Köln	Köln
Germany	H.O.T Praxis Landshut	Landshut
Germany	Lübecker Onkologische Schwerpunktpraxis	Lübeck
Germany	Gemeinschaftspraxis Haematologie und Onkologie	Magdeburg
Germany	Gemeinschaftspraxis für Hämatologie und Onkologie	Muenster
Germany	Brüderkrankenhaus St. Josef Paderborn	Paderborn
Germany	Gemeinschaftspraxis für Hämatologie und Onkologie	Ravensburg
Germany	Universitaetsklinikum Ulm	Ulm
Germany	Hämatologisch Onkologische Schwerpunktpraxis	Würzburg

Sponsors (1)

Lead Sponsor	Collaborator
German CLL Study Group

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR) at initial response assessment	Proportion of patients having achieved complete response (CR), complete response with incomplete bone marrow recovery (CRi) or partial response (PR) as response (according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines)	At initial response assessment (approx. 6 months after initiation of therapy)
Secondary	ORR at final restaging	Proportion of patients having achieved complete response (CR), complete response with incomplete bone marrow recovery (CRi) or partial response (PR) as response (according to the iwCLL 2018 guidelines)	At final restaging (approx. 24 months after initiation of therapy)
Secondary	Overall survival (OS)	Time from the date of registration to the date of death due to any cause	Up to 24 month
Secondary	Progression-free survival (PFS)	Time from the date of registration to the date of first occurrence of disease progression or relapse (according to iwCLL 2018 criteria) or death from any cause, whichever occurs first	Up to 24 month
Secondary	Event-free survival (EFS)	Time from the date of registration to the first occurrence of progression or relapse (according to iwCLL 2018 criteria), death from any cause or initiation of a subsequent anti-leukemic treatment, whichever occurs first	Up to 24 month
Secondary	Time to next CLL treatment (TTNT).	Time from date of registration to the date of initiation of subsequent anti-leukemic treatment	Up to 24 month
Secondary	Safety parameters: Adverse events (AE) and adverse events of special interest (AESI)	Type, frequency, and severity of AEs and AESIs	Up to 24 month

External Links

•   Click here for more information about this study: CLL-Frail (German CLL Study Group)